GRAIL Upgraded to Buy at TD Cowen

Analysts see upside potential in the cancer detection company's stock.

Mar. 21, 2026 at 8:18am

Got story updates? Submit your updates here. ›

TD Cowen upgraded shares of GRAIL (NASDAQ:GRAL) from a hold rating to a buy rating, setting a $65.00 price target on the stock. Several other equity analysts have also issued reports on GRAIL, with some cutting their price targets while others boosting their outlooks on the company's prospects.

Why it matters

GRAIL is a closely watched biotech company developing a multi-cancer early detection blood test. The analyst upgrades and mixed price target changes reflect the ongoing debate around GRAIL's technology, commercial potential, and valuation.

The details

In its research note, TD Cowen cited GRAIL's progress in developing its Galleri test, which aims to identify more than 50 types of cancer at their earliest stages by analyzing methylation patterns in circulating tumor DNA. Other analysts have taken a more cautious view, with Canaccord Genuity Group and Morgan Stanley lowering their price targets on GRAIL shares in recent months.

  • On Wednesday, March 21, 2026, TD Cowen upgraded GRAIL's stock rating.
  • In February 2026, Canaccord Genuity Group and Morgan Stanley cut their price targets on GRAIL.

The players

GRAIL, Inc.

A biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test.

TD Cowen

An investment bank that upgraded GRAIL's stock rating to buy from hold.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

GRAIL's stock continues to see volatility as analysts debate the company's technology and commercial prospects, underscoring the high stakes and uncertainty around early cancer detection breakthroughs.